Fund

Hengxu Capital

恒旭资本

Hengxu Capital (恒旭资本) shows up in elsewhere's corpus mostly as an active check-writer in recent Chinese AI and hard-tech rounds rather than through any dedicated profile. Per the deals on record, it co-led VAST's $50M Series A alongside Alibaba (announced by Oasis Capital in March 2026) , joined Galaxy Universal's 500M-yuan strategic round in late 2024 , and backed embodied-AI company Tashi Zhihang repeatedly — from its $120M angel round in March 2025 through a $455M Pre-A in April 2026, where it sat alongside industrial investors like TCL . Its reach isn't AI-only: it co-led Nutshell Therapeutics' $40M Series A+ with YuanBio Capital back in 2022 .

The corpus doesn't carry a standalone profile of the fund — no founding year, AUM, or team details — so what's visible is a pattern: an investor leaning into embodied intelligence, robotics, and frontier AI rounds across 2024–2026, with occasional life-science exposure earlier on.

AI-generated — may contain errors, please verify.

Hengxu CapitalFund
恒旭资本
渲染中…
Mentioned in 12 articles

Coverage